• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影像引导下调节门静脉血流的干预措施:证据与争议

Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

作者信息

Cannella Roberto, Tselikas Lambros, Douane Fréderic, Cauchy François, Rautou Pierre-Emmanuel, Duran Rafael, Ronot Maxime

机构信息

Université Paris Cité; AP-HP, Hôpital Beaujon, Service de Radiologie, Clichy; Centre de Recherche sur l'inflammation Inserm, UMR 1149, Paris, France.

Section of Radiology - Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital "Paolo Giaccone", Via del Vespro 129, 90127 Palermo, Italy.

出版信息

JHEP Rep. 2022 Apr 4;4(7):100484. doi: 10.1016/j.jhepr.2022.100484. eCollection 2022 Jul.

DOI:10.1016/j.jhepr.2022.100484
PMID:35677591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9168703/
Abstract

Portal hypertension is defined by an increase in the portosystemic venous gradient. In most cases, increased resistance to portal blood flow is the initial cause of elevated portal pressure. More than 90% of cases of portal hypertension are estimated to be due to advanced chronic liver disease or cirrhosis. Transjugular intrahepatic portosystemic shunts, a non-pharmacological treatment for portal hypertension, involve the placement of a stent between the portal vein and the hepatic vein or inferior vena cava which helps bypass hepatic resistance. Portal hypertension may also be a result of extrahepatic portal vein thrombosis or compression. In these cases, percutaneous portal vein recanalisation restores portal trunk patency, thus preventing portal hypertension-related complications. Any portal blood flow impairment leads to progressive parenchymal atrophy and triggers hepatic regeneration in preserved areas. This provides the rationale for using portal vein embolisation to modulate hepatic volume in preparation for extended hepatic resection. The aim of this paper is to provide a comprehensive evidence-based review of the rationale for, and outcomes associated with, the main imaging-guided interventions targeting the portal vein, as well as to discuss the main controversies around such approaches.

摘要

门静脉高压症是由门体静脉梯度增加所定义的。在大多数情况下,门静脉血流阻力增加是门静脉压力升高的初始原因。据估计,超过90%的门静脉高压症病例是由晚期慢性肝病或肝硬化引起的。经颈静脉肝内门体分流术是一种用于门静脉高压症的非药物治疗方法,涉及在门静脉与肝静脉或下腔静脉之间放置支架,以帮助绕过肝内阻力。门静脉高压症也可能是肝外门静脉血栓形成或受压的结果。在这些情况下,经皮门静脉再通可恢复门静脉主干通畅,从而预防门静脉高压症相关并发症。任何门静脉血流受损都会导致进行性实质萎缩,并触发保留区域的肝再生。这为使用门静脉栓塞术调节肝脏体积以准备进行扩大肝切除术提供了理论依据。本文的目的是对主要针对门静脉的影像引导干预措施的理论依据和相关结果进行全面的循证综述,并讨论围绕此类方法的主要争议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b909/9168703/87a7dd326b11/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b909/9168703/186a93175edf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b909/9168703/3f964e90636c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b909/9168703/87a7dd326b11/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b909/9168703/186a93175edf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b909/9168703/3f964e90636c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b909/9168703/87a7dd326b11/gr3.jpg

相似文献

1
Imaging-guided interventions modulating portal venous flow: Evidence and controversies.影像引导下调节门静脉血流的干预措施:证据与争议
JHEP Rep. 2022 Apr 4;4(7):100484. doi: 10.1016/j.jhepr.2022.100484. eCollection 2022 Jul.
2
Transsplenic portal vein recanalization and direct intrahepatic portosystemic shunt placement to optimize liver transplantation.经脾门静脉再通及直接肝内门体分流术以优化肝移植
CVIR Endovasc. 2020 Jan 8;3(1):5. doi: 10.1186/s42155-019-0096-7.
3
Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction.单纯门静脉再通术治疗非肝硬化慢性肝外门静脉阻塞患者的严重门静脉高压症。
JHEP Rep. 2022 May 25;4(8):100511. doi: 10.1016/j.jhepr.2022.100511. eCollection 2022 Aug.
4
Noncirrhotic portal hypertension.非肝硬化性门静脉高压症
J Clin Exp Hepatol. 2011 Sep;1(2):94-108. doi: 10.1016/S0973-6883(11)60128-X. Epub 2011 Nov 9.
5
Short- and long-term hemodynamic effects of transjugular intrahepatic portosystemic shunts: a Doppler/manometric correlative study.经颈静脉肝内门体分流术的短期和长期血流动力学效应:一项多普勒/测压相关性研究。
AJR Am J Roentgenol. 1995 Apr;164(4):997-1002. doi: 10.2214/ajr.164.4.7726065.
6
Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt (PVR-TIPS) with superior mesenteric vein access and balloon-assisted shunt placement.经肠系膜上静脉入路并采用球囊辅助分流器置入的门静脉再通-经颈静脉肝内门体分流术(PVR-TIPS)
CVIR Endovasc. 2023 Jun 8;6(1):33. doi: 10.1186/s42155-023-00379-6.
7
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a new strategy to increase resectability in liver surgery.联合肝脏离断和门静脉结扎的分阶段肝切除术(ALPPS):一种增加肝脏手术可切除性的新策略。
Int J Surg. 2014;12(5):437-41. doi: 10.1016/j.ijsu.2014.03.009. Epub 2014 Apr 2.
8
Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.经颈静脉肝内门体分流术时经皮穿刺左支门静脉以减少肝性脑病。
World J Gastroenterol. 2019 Mar 7;25(9):1088-1099. doi: 10.3748/wjg.v25.i9.1088.
9
Utility of Transjugular Intrahepatic Portosystemic Shunt Placement for Maintaining Portal Vein Patency in Candidates on Wait Lists Who Develop Thrombus.经颈静脉肝内门体分流术在等待血栓形成患者中维持门静脉通畅的效用。
Exp Clin Transplant. 2020 Dec;18(7):808-813. doi: 10.6002/ect.2019.0153. Epub 2019 Nov 13.
10
Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis.系统评价与荟萃分析:门静脉再通和经颈静脉肝内门体分流术治疗门静脉血栓。
Aliment Pharmacol Ther. 2019 Jan;49(1):20-30. doi: 10.1111/apt.15044. Epub 2018 Nov 18.

引用本文的文献

1
5-hydroxymethylcytosine features of portal venous blood predict metachronous liver metastases of colorectal cancer and reveal phosphodiesterase 4 as a therapeutic target.门静脉血中5-羟甲基胞嘧啶特征可预测结直肠癌异时性肝转移并揭示磷酸二酯酶4作为治疗靶点。
Clin Transl Med. 2025 Feb;15(2):e70189. doi: 10.1002/ctm2.70189.

本文引用的文献

1
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识:门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
2
Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome.直接肝内门腔分流术(DIPS)或经颈静脉肝内门体分流术(TTIPS)治疗门脉高压并发症:布加综合征以外的适应证、技术和结果。
Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101858. doi: 10.1016/j.clinre.2022.101858. Epub 2022 Jan 7.
3
TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy.
成人非肝硬化合并慢性肠系膜静脉血栓形成和对标准治疗难治性 EHPVO 的 TIPS 治疗。
Hepatology. 2021 Nov;74(5):2735-2744. doi: 10.1002/hep.31915. Epub 2021 Jul 8.
4
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation.使用新型VIATORR®可控扩张支架进行控制性扩张不足可提高经颈静脉肝内门体分流术植入后的生存率。
JHEP Rep. 2021 Mar 3;3(3):100264. doi: 10.1016/j.jhepr.2021.100264. eCollection 2021 Jun.
5
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.腹水、自发性细菌性腹膜炎和肝肾综合征的诊断、评估及管理:美国肝病研究协会2021年实践指南
Hepatology. 2021 Aug;74(2):1014-1048. doi: 10.1002/hep.31884.
6
BestFLR Trial: Liver Regeneration at CT before Major Hepatectomies for Liver Cancer-A Randomized Controlled Trial Comparing Portal Vein Embolization with -Butyl-Cyanoacrylate Plus Iodized Oil versus Polyvinyl Alcohol Particles Plus Coils.BestFLR 试验:肝癌根治性肝切除术前 CT 下肝脏再生-经门静脉栓塞术与 -丁基氰基丙烯酸酯碘化油对比聚乙烯醇颗粒加线圈的随机对照试验
Radiology. 2021 Jun;299(3):715-724. doi: 10.1148/radiol.2021204055. Epub 2021 Apr 6.
7
A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma.门静脉栓塞与钇-90 微球放射肝段切除术治疗初始不可切除肝细胞癌的对比研究。
Surgery. 2021 May;169(5):1044-1051. doi: 10.1016/j.surg.2020.12.012. Epub 2021 Feb 27.
8
Safety and Efficacy of Endovascular Treatment of Portal Vein Stenosis in Liver Transplant Recipients: A Systematic Review.肝移植受者门静脉狭窄的血管内治疗的安全性和疗效:系统评价。
Vasc Endovascular Surg. 2021 Jul;55(5):452-460. doi: 10.1177/1538574421994417. Epub 2021 Feb 23.
9
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.利福昔明在经颈静脉肝内门体分流术后预防显性肝性脑病中的应用:一项随机对照试验。
Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2.
10
Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.使用新型弗赖堡经颈静脉肝内门体分流术后生存指数优化经颈静脉肝内门体分流术后生存预测。
J Hepatol. 2021 Jun;74(6):1362-1372. doi: 10.1016/j.jhep.2021.01.023. Epub 2021 Jan 26.